Background. The US Advisory Committee on Immunization Practices recommends a booster dose of quadrivalent meningococcal conjugate vaccine (MCV4) after initial immunization for patients at high risk for meningococcal infection.
Previous studies have shown that human immunodeficiency virus (HIV) infection can impair the development of protective immunity in response to vaccines in childhood [1] [2] [3] . The P1065 study conducted by the International Maternal Pediatric Adolescents AIDS Clinical Trials (IMPAACT) network found that HIV-infected youth are at increased risk for an immunogenic response to 1 dose of quadrivalent meningococcal conjugate vaccine (MCV4) that is lower than that of healthy adolescents [4] and have higher immunogenicity after an initial 2-dose series of MCV4 than after a single MCV4 dose [5] .
The Advisory Committee for Immunization Practices of the Centers for Disease Control and Prevention recommends that patients previously vaccinated with MCV4 who remain at increased risk for meningococcal disease be revaccinated with MCV4 [6] . For those who received their first MCV4 at 7 years of age or older, it is now recommended that MCV4 be administered at 5-year intervals for as long as they are at an increased risk for meningococcal disease, although the effectiveness of this specific interval is not known.
In the P1065 study, antibody titers declined substantially by 72 weeks after the initial MCV4 dose even among those who received 2 doses [5, 7] , which suggests that HIV-infected youth who received either a single dose or 2-dose series of MCV4 would likely benefit from an additional MCV4 dose. Therefore, in light of the Advisory Committee for Immunization Practices recommendations, the P1065 study was amended to examine the effectiveness of a booster vaccination. Participants were approached for participation in this follow-up step to study booster vaccination 3.5 years after the primary MCV4 study vaccine series.
IMPAACT network in the United States. Included were 3 groups of participants: 11-to 24-year-olds with a screening CD4 cell percentage (CD4%) of ≥15 (group 1), 11-to 24-yearolds with a CD4% of <15 (group 2), and 2-to 10-year-olds with a CD4% of ≥25 (group 3). At study entry (step 1), each participant received the MCV4 vaccine (Menactra [SanofiPasteur, Swiftwater, PA]; 0.5 mL intramuscularly). After 24 weeks, participants were entered onto step 2, in which those in group 1 who had not had any adverse reactions precluding MCV4 were assigned randomly in a 1:1 ratio to receive a second dose or no second dose; all group 2 and 3 participants received a second dose. Participants from groups 1 and 3 with data from weeks 0, 4, and 28 were eligible to enroll onto step 3 of the study. Group 2 was excluded, because there were too few eligible participants to provide adequate precision for estimates.
Step 3 of this study was designed to assess immunogenicity and response to an additional MCV4 (booster) dose 3.5 years (±6 months) after initial vaccination. Participants were administered a single dose of MCV4 at the step 3 entry visit and were followed up for 24 weeks after vaccination.
P1065 Participants
To be eligible for P1065, participants must have been on a stable regimen of antiretroviral treatment (ART) or have not received ART for at least 90 days before vaccination. Highly active ART (HAART) was defined as the use of at least 3 antiretroviral drugs from at least 2 classes. Exclusion criteria included family (parent, sibling, or child) or personal history of Guillain-Barré Syndrome (GBS), or having received meningococcal conjugate vaccine at any time or having received meningococcal polysaccharide vaccine within the 2 years before study entry. Participants entered the study between July 2007 and December 2008.
The 226 group 1 participants and 49 group 3 participants who participated in both steps 1 and 2 and for whom we had serologic data from weeks 0, 4, and 28 were approached to enroll onto step 3 (booster vaccination). Estimating a 20% to 30% rate of nonparticipation, the final group was anticipated to include approximately 158 to 180 group 1 participants and 34 to 40 group 3 participants for a total of 192 to 220 participants. This sample size would provide relatively precise estimates of rates of protective antibody titers at step 3 entry and response rates after the booster dose of MCV4 (half-width of 95% confidence intervals ranging from 4.5% to 6.8% for a total group size of 192 and 4.2% to 6.7% for a total group size of 220).
Safety
Participants remained in the clinic for at least 30 minutes after vaccine administration so that clinic personnel could observe any adverse reactions to the vaccine; the participants were also evaluated at week 1 for vaccine adverse reactions. Participants were evaluated for signs and symptoms of GBS using a standardized questionnaire at the week 4 and 24 visits. The safety of MCV4 administration was assessed by evaluating the development of GBS, meningitis, or death along with new grade 3 or higher adverse events (AEs) according to the December 2004 Division of AIDS AE grading table [8] . AEs were assessed on the basis of laboratory evaluations of hematologic parameters, signs and symptoms, local vaccine injection-site reactions, and AE reports.
Immunogenicity
Functional meningococcal antibody activity against serogroups A, C, Y, and W-135 was measured by serum bactericidal assay using a baby rabbit complement source (rSBA). Serogroupspecific meningococcal bacteria, baby rabbit complement, and serially diluted serum were incubated together in sterile microtiter plates. An agar overlay medium was added to the serumcomplement-bacteria mixture, and the plates were incubated again. The number of resulting bacterial colonies present in the wells was inversely proportional to the level of functional antibody present in the serum. The endpoint titer was determined by the reciprocal serum dilution that yielded ≥50% killing compared to the mean killing of the complement control wells that contained no serum. The lower limit of detection was a titer of 8. Samples with no detectable antibody were assigned a titer of 4 for the calculation of geometric mean titers (GMTs). All assays were performed by SanofiPasteur in batches at the end of the study steps.
There were 3 primary measures of immunogenicity: (1) seroprotection (measured at weeks 0, 1, and 4) was defined as an rSBA titer of ≥1:128; (2) immunologic memory was defined as having either a secondary (anamnestic) response (defined as a 4-fold rise in rSBA titer between weeks 0 [booster dose] and 1) or seroprotection at entry or by week 1; and (3) primary immunogenic response (suggestive of a response to the vaccine dose but not suggestive of immunologic memory) was defined as (a) a 4-fold rise in the rSBA concentration between weeks 0 and 4 but not between weeks 0 and 1 or (b) change from a titer of <1:128 on day 0 to ≥1:128 at week 4 but not between weeks 0 and 1.
Statistical Methods
Outcome rates and exact confidence intervals for each serogroup were calculated using the above-listed definitions. In addition, GMTs were calculated for each serogroup. Standard errors for the estimated rates were based on binomial distribution. Comparisons were made using the Fisher's exact, Pearson χ 2 , or Kruskal-Wallis test, as appropriate. Three posthoc analyses were also conducted using the Fisher's exact test.
To evaluate all types of responses, it was necessary to use antibody data from weeks 0, 1, and 4. For that reason, all immunogenicity analyses were restricted to participants for whom we had data from those 3 time points. Statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC). A 2-sided significance level of .05 was used for statistical significance.
Each site received approval for the study through its local institutional review board (IRB). Participants or their parents/guardians signed informed consent before participation; written assent was obtained as required by the local IRBs. This study was registered with ClinicalTrials.gov (identifier NCT00459316).
RESULTS

Study Population
One hundred ninety-two participants enrolled onto step 3 between January 2011 and August 2012; 188 (98%) completed the protocol. Four participants withdrew early (1 was not able to get to the clinic, and 3 were lost to follow-up). Participant characteristics at study entry were reported previously [2, 3] . At step 3 entry, the median (interquartile range [IQR] ) ages were 20 years (17.5-25 years) for group 1 and 9 years (8-11 years) for group 3 (Table 1) ; 58% were male, 51% were black, and 36% were Hispanic/Latino. The median (IQR) CD4% at step 3 entry was 32 (26-39), 66% had a viral load of <400 copies per mL, 24% had a history of Centers for Disease Control and Prevention Class C [9] conditions (eg, acquired immunodeficiency syndrome-defining diagnoses), and 89% were receiving HAART at step 3 entry. No statistically significant differences between groups 1 and 3 were found.
Safety
The most severe vaccine reaction found was grade 2 (moderate), reported by 6 (3%) of the participants; an additional 22 (11%) participants had grade 1 (mild) vaccine reactions. Reactions were predominantly pain and tenderness at the injection site. Two (1%) grade 3 AEs were reported at week 24, post-tonsillectomy pain and hyperglycemia, neither of which was judged to be related to the study vaccine. No deaths occurred, and no cases of GBS or meningococcal meningitis were reported.
Immunogenicity
Of the 192 participants in step 3, 174 (91%) had available data from weeks 0, 1, and 4 for all serogroups. Participants with complete response data available were similar to those without, except those without the available data had a lower CD4% (median, 25% vs 32%, respectively; P = .02, Fisher's exact test) and a higher HIV RNA viral load (44% vs 68% with <400 copies per mL, respectively; P = .04, Fisher's exact test) at step 3 entry.
Step 3 Entry
The GMTs at step 3 entry were 107 for serogroup A, 17 for serogroup C, 58 for serogroup W-135, and 71 for serogroup Y, all of which were higher than those at step 1 entry (see Table 2 for GMTs at all step 3 time points; see Supplementary Table 1 for step 1 time-point data). The percentages of participants with a protective antibody level varied according to serogroup, from a low of 26% for serogroup C to a high of 68% for serogroup A (Table 3) . We found no significant differences for any of the serogroups among the group 1 CD4% subgroups (P = .09 to Abbreviations: GMT, geometric mean titer; LCL, lower 95% confidence limit; UCL, upper 95% confidence limit.
.72, Fisher's exact test), group 3 age subgroups (P = .15 to >.99, Fisher's exact test), or between group 1 participants who had received 1 versus those who had received 2 doses in step 2 (P = .13 to >.99, Fisher's exact test).
Vaccine Response
Across all serogroups, for the vast majority of the participants, we found evidence of immunologic memory from the primary vaccine series. More than three-quarters of them had a ≥4-fold anamnestic response at week 1, and ≥87% had seroprotection at week 0 (step 3 entry); the rate of participants who had at least 1 type of immunologic memory was ≥88% for each serogroup (Table 4 ). The proportions of those without immunologic memory who had primary responses were 31% (4 of 13) for serogroup A, 14% (3 of 18) for serogroup C, 27% (3 of 11) for serogroup W-135, and 42% (5 of 12) for serogroup Y. Overall, the rates of any memory or primary response were ≥90% for all serogroups, higher than the response rates to the initial vaccination in step 1 (52%-73%) [2] . For group 1 participants, we found no statistically significant differences in immunologic memory or primary response rates in those who had received 1 versus those who had received 2 doses (Supplementary Table 2 . Differences in immunologic memory rates in the group 1 treatment arm ranged from 0% to 5% (P = .38 to >.99, Fisher's exact test) and went in both directions. GMTs at week 4 were substantially higher than those at step 3 entry and higher than those 4 weeks after the initial step 1 vaccination for serogroups C, W-135, and Y with nonoverlapping 95% confidence limits (Table 1) .
There were only 4 participants showing no evidence of immunologic memory to any serogroup; 2 of these also did not have primary responses to any serogroup. For each of these participants, we found a detectable plasma HIV RNA level (602-12 936 copies per mL) and rSBA titers of <8 for all serogroups at step 3 entry; they were heterogeneous in terms of entry strata and step 2 treatment. The 2 participants with no memory or primary responses, and 1 participant with only primary responses, had not responded to any serogroups at step 1.
Predictors
Because immunological memory and response rates were higher than expected for all serogroups and no differences were found between group 1 treatment arms, 3 sets of posthoc analyses of possible predictors of response were performed to better understand responses to the booster vaccination.
Antibody Titer at
Step 3 Entry. An antibody titer of ≥1:128 has been considered the level needed for protection, although ≥1:8 [9] might be adequate. All participants with entry rSBA titers of ≥128 or with rSBA titers of 8 to <128 for serogroups A, C, and W-135 had immunologic memory or primary responses to the booster vaccination, as did 95% of those with an entry titer of 8 to <128 for serogroup Y. Rates were lower but still very high for those with entry titers below the limit of detection (<8), ranging from 81% to 89% (P = .002 to <.001, Fisher's exact test) (Supplementary Table 3 ).
Initial Vaccine Response.
The results for booster vaccination indicate that even participants who did not have 4-fold responses to the initial MCV4 vaccination had high rates of immunologic memory or response. As expected, step 1 response was associated with step 3 immunologic memory or primary response (P = <.001 to .02, Fisher's exact test). For each serogroup, ≥97% of those who responded to the first dose of MCV4 had either immunologic memory or primary response to the booster vaccination. For those who did not respond in step 1, the rates for all serogroups were still ≥75% (Supplementary Table 4) . (2) 3 (2) 3 (2) 5 (3) Memory or primary response 165 (95) 156 (90) 166 (95) 167 (96) a Memory: a 4-fold rise in rabbit serum bactericidal antibody (rSBA) titers between weeks 0 and 1 or seroprotection at entry or by week 1. b Primary response: a 4-fold rise in rSBA concentration between weeks 0 and 4 but not between weeks 0 and 1 or change from a titer of <1:128 on day 0 to ≥1:128 at week 4 but not between weeks 0 and 1.
Entry CD4% Stratum. At entry onto step 1, group 1 participants were stratified according to their CD4%, 15 to <24 vs ≥25. For all serogroups, rates were lower for participants in the 15 to <24 stratum; this result was statistically significant for serogroup C (72% vs 96%; P < .001, Fisher's exact test) (Supplementary Table 5 ). Because of the small number of participants without immunologic memory or primary responses for the other serogroups, there was limited power to detect differences.
DISCUSSION
A booster MCV4 vaccination 3.5 years after the original dose was safe for HIV-infected children and youth. Rates of severe AEs were very low (1%) and were not related to vaccination. Vaccine reactions, mainly injection-site pain/tenderness, pruritus, edema, and headache, were mild or moderate. No deaths occurred, and no cases of GBS or meningitis were reported. For each serogroup, the vast majority (88%-94%) of participants had immunologic memory to the booster vaccination, and 90% to 96% had either memory or primary responses. As in previous steps of the study [4, 5, 7] , rates were lower for serogroup C than for the other serogroups. For participants from group 1, we found no significant differences in evidence of immunologic memory or response rates between the 1-dose and 2-dose treatment arms. Only 4 participants had no immunologic memory to any serogroups; they all had titers below the level of detection for all serogroups at step 3 entry, and 3 of them had had no responses to any serogroups with the original vaccination.
Posthoc analyses revealed that, for all serogroups, participants who responded to a serogroup after their initial vaccination were significantly more likely to have an immunologic memory or primary response to that serogroup at step 3; rates were still very high for those who did not have a response in step 1 (≥75% for each serogroup). For group 1 participants, rates were higher for participants with a CD4% of ≥25 at study entry than for those with a CD4% of 15 to <25, similar to findings for other vaccines in HIV-positive youth [3, 10] .
rSBA titers at the time of the booster vaccine dose were significantly associated with having immunologic memory or primary responses for all the serogroups. rSBA titers of ≥1:128 have been found to be highly predictive of protection and evidence of protection from titers in the range of 1:8 to 1:65 is equivocal [11] . In the P1065 study, for almost every participant with a titer between 1:8 and <1:128 at the time of the booster dose, we found evidence of immunologic memory. Even participants with titers below the level of detection at the time of the booster dose had very high rates of memory or primary response (81%-89%).
A strength of this study is that it followed participants from before their first vaccination, which gave us a longitudinal view of responses to the initial vaccination, the second dose (for some participants), and the booster vaccination. A limitation is that only participants who entered the study with a CD4% of ≥15 were eligible for step 3; therefore, we lack information on how more severely immunocompromised participants would respond to booster vaccination. Also, because we had different eligibility criteria for groups 1 and 3, we were unable to evaluate differences in responses according to age by making comparisons across age groups.
In conclusion, a booster dose of the MCV4 vaccine is safe and effective in HIV-infected children and youth with a CD4% of ≥15. The high rates of immunologic memory seen across all subgroups in this study provide supporting evidence for the effectiveness of the initial step 1 MCV4 vaccination 3.5 years earlier in establishing a memory response. The lack of difference in response rates between those who received 1 versus those who received 2 doses in step 1 suggests that a second dose 6 months after the initial immunization might not increase memory response or long-term vaccination effectiveness, which could merit examination in future studies. In addition, the strong and rapid booster responses seen even among participants who had undetectable levels of antibodies at step 3 entry suggest that HIV infection does not materially impair longterm immune memory responses to successful initial conjugate meningococcal vaccination.
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